← Back to Clinical Trials
Recruiting NCT06282562

NCT06282562 FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06282562
Status Recruiting
Phase
Sponsor Amsterdam UMC, location VUmc
Condition Brain Tumor, Primary
Study Type INTERVENTIONAL
Enrollment 36 participants
Start Date 2024-01-01
Primary Completion 2026-08-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
High-Intensity Interval Training (HIIT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 36 participants in total. It began in 2024-01-01 with a primary completion date of 2026-08-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The FeelFit study aims to assess the effectiveness of High-Intensity Interval Training (HIIT) in improving self-reported physical fitness in adult brain tumor patients during periods of stable disease, as compared to a waiting-list control group. Furthermore, several secondary and exploratory outcomes will be evaluated. The study is part of the GRIP (GuaRding quality survivorshiP) project, which aims to improve quality of life in brain tumor patients.

Eligibility Criteria

Inclusion Criteria: * reduced self-reported physical fitness; * minimum age of 18 years; * diagnosed with a primary brain tumor; * stable disease, i.e. no signs of radiological or clinical tumor progression; * no oncological treatment for at least two months prior to inclusion; * able to speak, read and write in Dutch. Exclusion Criteria: * Karnofsky Performance Score \< 70; * already participated in a HIIT program \< 1 month prior; * contraindication of exercise.

Contact & Investigator

Central Contact

Marieke Blom, Msc

✉ m.e.c.blom@amsterdamumc.nl

📞 +31 6 21522442

Frequently Asked Questions

Who can join the NCT06282562 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumor, Primary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06282562 currently recruiting?

Yes, NCT06282562 is actively recruiting participants. Contact the research team at m.e.c.blom@amsterdamumc.nl for enrollment information.

Where is the NCT06282562 trial being conducted?

This trial is being conducted at Amsterdam, Netherlands.

Who is sponsoring the NCT06282562 clinical trial?

NCT06282562 is sponsored by Amsterdam UMC, location VUmc. The trial plans to enroll 36 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology